Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 4/20 | 0.53 |
| ▸ | KCNK9 | Q9NPC2 | 4/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29344027 | 1.00 | KCNK3 (0.53) | KCNK3KCNK9SIGMAR1KMT2AL3MBTL1 | |
| SCHEMBL1365607 | 0.90 | HSD11B1 (0.48) | KCNK3KCNK9SIGMAR1KMT2AL3MBTL1 | |
| SCHEMBL18112122 | 0.90 | HSD11B1 (0.48) | KCNK3KCNK9SIGMAR1KMT2AL3MBTL1 | |
| SCHEMBL8013274 | 0.90 | HSD11B1 (0.48) | KCNK3KCNK9SIGMAR1KMT2AL3MBTL1 | |
| SCHEMBL928364 | 0.90 | HSD11B1 (0.48) | KCNK3KCNK9SIGMAR1KMT2AL3MBTL1 | |
| SCHEMBL24649336 | 0.86 | KCNK3 (0.43) | KCNK3KCNK9SIGMAR1KMT2AL3MBTL1 | |
| SCHEMBL30695227 | 0.86 | KCNK3 (0.43) | KCNK3KCNK9SIGMAR1KMT2AL3MBTL1 | |
| SCHEMBL24649043 | 0.84 | KMT2A (0.42) | KCNK3KCNK9SIGMAR1KMT2AL3MBTL1 | |
| SCHEMBL27044069 | 0.84 | KMT2A (0.42) | KCNK3KCNK9SIGMAR1KMT2AL3MBTL1 | |
| SCHEMBL24649349 | 0.84 | KMT2A (0.42) | KCNK3KCNK9SIGMAR1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | KCNK3 3840/4885KCNK9 3730/4885SIGMAR1 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.